title: Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial.
abstract: BACKGROUND
  A multicenter, double blinded, randomized phase III trial of the therapeutic cancer vaccine sialy1-Tn (STn) conjugated to keyhole-limpet Hemocyanin (KLH) was completed in an international cohort of 1,028 women with metastatic breast cancer who had nonprogressive disease or no evidence of disease after first-line chemotherapy (ClinicalTrials.gov, (NCT00003638). STn-KLH was safe and relatively well tolerated but did not affect time to progression (TTP) or overall survival (OS) duration. The purpose of this post hoc analysis was to explore whether patients who received concurrent endocrine therapy and STn-KLH had a TTP or OS benefit.
  
  
  METHODS
  A retrospective, blinded review of the data from the phase III trial of STn-KLH was performed to ensure that strata assignments were appropriate. We then studied the effect of concomitant endocrine therapy and STn-KLH or KLH on TTP and OS in the cohort described above. We also assessed the TTP and OS by antibody responses in patients who received endocrine therapy.
  
  
  RESULTS
  The women treated with concomitant endocrine therapy, a pre-stratified subset comprising approximately one-third of the original study population, and STn-KLH had longer TTP and OS than the control group of women who received KLH alone. Moreover, of the women who received endocrine therapy, those who had a median or greater antibody response (titer >1:320 toward ovine sub maxillary mucin) to the STn-KLH vaccine had significantly longer median OS than those who had a below-median antibody response.
  
  
  CONCLUSIONS
  Adding STn-KLH to endocrine therapy may improve clinical outcomes with few adverse effects for women with metastatic breast cancer.
authors: 1. Departments of Breast Medical Oncology (NKI, JLM), Melanoma Medical Oncology (DZ), and Surgical Oncology (EAM), The University of Texas MD Anderson Cancer Center, Houston, TX;
authors: Nuhad K
authors: NK
authors: Ibrahim
authors: James L
authors: JL
authors: Murray
authors: Dapeng
authors: D
authors: Zhou
authors: Elizabeth A
authors: EA
authors: Mittendorf
authors: Dory
authors: D
authors: Sample
authors: Michael
authors: M
authors: Tautchin
authors: David
authors: D
authors: Miles
keywords: keyhole-limpet Hemocyanin; metastatic breast cancer; sialy1-Tn
references: J Immunother Emphasis Tumor Immunol. 1996 Jan;19(1):59-68
references: 8859725
references: Clin Breast Cancer. 2001 Jan;1(4):276-87
references: 11899350
references: J Cancer Res Clin Oncol. 2001 Oct;127 Suppl 2:R20-6
references: 11768620
references: Clin Breast Cancer. 2003 Feb;3 Suppl 4:S134-8
references: 12620150
references: Glycoconj J. 1997 Aug;14(5):549-60
references: 9298687
references: Expert Rev Vaccines. 2004 Dec;3(6):655-63
references: 15606349
references: Eur J Surg Oncol. 2001 Dec;27(8):731-9
references: 11735169
references: Histopathology. 2007 Sep;51(3):322-35
references: 17645748
references: Oncologist. 2011;16(8):1092-100
references: 21572124
references: Cancer. 1997 Dec 15;80(12):2240-9
references: 9404700
references: Cancer Immunol Immunother. 1993;36(4):215-22
references: 8439984
references: Semin Oncol. 2002 Jun;29(3 Suppl 11):53-61
references: 12138398
references: Expert Opin Biol Ther. 2001 Sep;1(5):881-91
references: 11728222
references: Mol Cell. 2006 Jan 20;21(2):295-305
references: 16427018
references: Clin Breast Cancer. 2003 Feb;3 Suppl 4:S144-51
references: 12620152
references: Clin Cancer Res. 2011 Nov 1;17(21):6822-30
references: 21878535
references: Br J Cancer. 1996 Oct;74(8):1292-6
references: 8883420
references: Curr Opin Investig Drugs. 2001 Jan;2(1):133-5
references: 11527005
references: Ann N Y Acad Sci. 1993 Aug 12;690:276-91
references: 7690215
references: Br J Cancer. 2009 Jun 2;100(11):1746-54
references: 19436292
references: Expert Rev Anticancer Ther. 2008 Dec;8(12):1907-12
references: 19046111